# Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

> **NCT03629925** · PHASE3 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 357 (actual)

## Conditions studied

- Squamous NSCLC

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Placebo
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03629925
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-28
- **Primary completion:** 2020-03-25
- **Final completion:** 2021-09-30
- **Target enrollment:** 357 (ACTUAL)
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03629925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03629925, "Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03629925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*